Lv11
40 积分 2025-02-27 加入
US Food and Drug Administration Approval Summary: Talazoparib in Coh Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
6小时前
待确认
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
13小时前
已完结
Autocrine 17-b-Estradiol/Estrogen Receptor-a Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
2个月前
已关闭
Estrogen, estrogen receptor and the tumor microenvironment of NSCLC
2个月前
已完结
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer之前DOI号填错
2个月前
已完结
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
2个月前
已关闭
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
3个月前
已完结
Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study
4个月前
已完结
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
